Two FDA updates matter to readers comparing menopause care in 2026. February brought labeling changes for six products. September brought an update about difficulty obtaining some estradiol patches.
One concerns prescribing information; the other concerns access to supply. Neither tells an individual to start hormones, stop treatment or replace a medicine without a clinician’s guidance.
In this entry
The February labeling action
The FDA announced that statements about cardiovascular disease, breast cancer and probable dementia were removed from the boxed warning for the affected products. Its published list named Prometrium, Divigel, Cenestin, Enjuvia, Estring and Bijuva.
Those names span different formulations and uses. Avoid describing the action as though every hormone product received an identical label change. The agency’s list links to updated information, which is more useful than an old image of a warning leaflet.
The individual risk conversation remains
A revised warning does not eliminate the relevance of age, time since menopause, route, dose or personal history. A clinician still needs to consider conditions such as unexplained bleeding, previous clots, certain cancers, heart disease and liver disease.
The starting-after-50 guide explains the role of timing. If a past warning made you avoid asking about treatment, the update is a reason to reopen the discussion with current information—not a reason to self-prescribe.
Compounded medicines did not become approved
The February action involved approved products. It does not supply FDA approval to a customized estrogen or progesterone preparation. A provider should not treat a label revision for another drug as evidence that its own compound has been evaluated in the same way.
Read approved versus compounded HRT to separate these claims. Approval status belongs to the finished product, not a broad marketing category.
The September access update
On September 3, the FDA acknowledged reports of difficulty finding usual estradiol transdermal patches. It noted variation by product, pharmacy and location and described manufacturer efforts to increase supply. The notice did not establish that every patch was unavailable everywhere.
The agency advised contacting a pharmacist about an appropriate available patch and discussing alternatives with the prescriber. Our refill guide turns that advice into practical questions about quantity, timing and coordination.
Keep the two updates in their proper place
A product can have updated prescribing information and still be hard to obtain locally. An available product can still be unsuitable for a particular person. A compounded preparation can be obtainable without being an equivalent substitute.
Ask the clinician to identify the exact medicine and explain its current instructions. Ask the pharmacy about actual stock and any needed authorization. This article reports the official notices as checked on September 20, 2026; it does not monitor every label revision or pharmacy shelf in real time.
CHECK THE ORIGINAL
The source record
Provider pages document their own offers. Medical and regulatory sources provide treatment context. This is not a record of personal patient testing. All sources checked September 20, 2026.